There are no clinical trials that compare the two most used neoadjuvant treatment schemes in HER2-positive early breast cancer; the BERENICE protocol with anthracyclines and TRAIN-2 protocol without anthracyclines. This evidence concerns the gene ERBB2 and breast carcinoma.